Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.

Prostate-specific membrane antigen (PSMA) is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer (PC), making it an optimal target for the treatment of metastasized PC.

Radioligand therapy (RLT) with 177Lu-PSMA-DKFZ-617 (Lu-PSMA) is a targeted therapy for metastatic PC. In this study, we retrospectively analyzed the side effects and the response rate of 24 hormone and/or chemorefractory PC patients with a mean age of 75. 2 years (range: 64-82) with distant metastases and progressive disease according to the PSA level, who were treated with Lu-PSMA. Median PSA was 522 ng/ml (range: 17-2360). Forty-six cycles of Lu-PSMA were performed. Of the 24 patients, 22 received two cycles. Eight weeks after the first cycle of Lu-PSMA therapy 79. 1% experienced a decline in PSA level. Eight weeks after the second cycle of Lu-PSMA therapy 68. 2% experienced a decline in PSA relative to the baseline value. Apart from two cases of grade 3 anemia, there was no relevant hemato- or nephrotoxicity (grade 3 or 4). These results confirmed that Lu-PSMA is a safe treatment option for metastatic PC patients and has a low toxicity profile. A positive response to therapy in terms of decline in PSA occurs in about 70% of patients.

Oncotarget. 2016 Feb 08 [Epub ahead of print]

Hojjat Ahmadzadehfar, Elisabeth Eppard, Stefan Kürpig, Rolf Fimmers, Anna Yordanova, Carl Diedrich Schlenkhoff, Florian Gärtner, Sebastian Rogenhofer, Markus Essler

Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. , Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. , Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. , Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany. , Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. , Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. , Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. , Department of Urology, University Hospital Bonn, Bonn, Germany. , Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.

PubMed